Positive News SentimentPositive NewsNASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $105.84 -5.70 (-5.11%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$105.60▼$111.3150-Day Range$87.37▼$115.9652-Week Range$22.81▼$117.88Volume376,227 shsAverage Volume690,947 shsMarket Capitalization$5.79 billionP/E RatioN/ADividend YieldN/APrice Target$124.27Consensus RatingModerate Buy Company Overview Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 595th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingDianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $124.27, representing about 17.4% upside from its current price of $105.84.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.83) to ($4.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -25.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -25.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.88% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 11.54, which indicates bearish sentiment.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 0.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. News and Social Media4.7 / 5News Sentiment1.56 News SentimentDianthus Therapeutics has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Dianthus Therapeutics this week, compared to 6 articles on an average week.Search Interest5 people have searched for DNTH on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows3 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,615,923.00 in company stock.Percentage Held by Insiders3.02% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesDianthus Therapeutics (DNTH) Gets a Buy from Truist FinancialAugust 28 at 10:26 AM | theglobeandmail.comDianthus Therapeutics: The C1s Shakeout Strengthens The Bull CaseAugust 25, 2026 | seekingalpha.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.August 30 at 1:00 AM | Porter & Company (Ad)Analysts Are Bullish on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Nyxoah (NYXH)August 21, 2026 | theglobeandmail.comInsider Selling: Dianthus Therapeutics (NASDAQ:DNTH) Director Sells $326,553.90 in StockAugust 20, 2026 | insidertrades.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 19, 2026 | americanbankingnews.comInsider Selling: Dianthus Therapeutics (NASDAQ:DNTH) Director Sells $304,220.35 in StockAugust 12, 2026 | insidertrades.comDianthus Therapeutics (NASDAQ:DNTH) CEO Sells $17,946,260.00 in StockAugust 8, 2026 | insidertrades.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $41.21 at the beginning of the year. Since then, DNTH stock has increased by 156.8% and is now trading at $105.84. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its earnings results on Tuesday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.05. The business earned $0.76 million during the quarter, compared to analysts' expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative trailing twelve-month return on equity of 22.53%. When did Dianthus Therapeutics IPO? Dianthus Therapeutics (DNTH) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Dianthus Therapeutics' major shareholders? Top institutional investors of Dianthus Therapeutics include BlackRock Inc. (7.54%), California State Teachers Retirement System (7.50%), Wellington Management Group LLP (5.91%) and Braidwell LP (1.09%). Insiders that own company stock include Fairmount Funds Management Llc, Marino Garcia, Ryan Savitz, Simrat Randhawa, Adam M Veness, Simon Read, Anne Mcgeorge and Edward Carr. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/04/2026Today8/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 DNTH's financial health is in the Green zone, according to TradeSmith. DNTH has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$124.27 High Price Target$158.00 Low Price Target$98.00 Potential Upside/Downside+17.4%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.34 million Net Margins-10,096.95% Pretax Margin-10,096.95% Return on Equity-22.53% Return on Assets-21.55% Debt Debt-to-Equity RatioN/A Current Ratio26.10 Quick Ratio26.10 Sales & Book Value Annual Sales$1.90 million Price / Sales3,038.79 Cash FlowN/A Price / Cash FlowN/A Book Value$21.44 per share Price / Book4.94Miscellaneous Outstanding Shares54,666,000Free Float53,015,000Market Cap$5.79 billion OptionableOptionable Beta1.22 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DNTH) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...Brownstone Research | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
